These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 16389162)
21. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680 [TBL] [Abstract][Full Text] [Related]
22. Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study. Musholt PB; Schöndorf T; Pfützner A; Hohberg C; Kleine I; Fuchs W; Hehenwarter S; Dikta G; Kerschgens B; Forst T J Diabetes Sci Technol; 2009 Nov; 3(6):1442-50. PubMed ID: 20144400 [TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of combined therapy for type 2 diabetes. Rodríguez A; Ciprés L; Tofé S; Polavieja P; Reviriego J Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952 [TBL] [Abstract][Full Text] [Related]
24. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA; Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300 [TBL] [Abstract][Full Text] [Related]
25. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641 [TBL] [Abstract][Full Text] [Related]
26. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411 [TBL] [Abstract][Full Text] [Related]
27. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Goldstein BJ; Weissman PN; Wooddell MJ; Waterhouse BR; Cobitz AR Curr Med Res Opin; 2006 Sep; 22(9):1715-23. PubMed ID: 16968575 [TBL] [Abstract][Full Text] [Related]
28. Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. Moon JH; Kim HJ; Kim SK; Kang ES; Lee BW; Ahn CW; Lee HC; Cha BS Metabolism; 2011 Feb; 60(2):165-72. PubMed ID: 20092860 [TBL] [Abstract][Full Text] [Related]
29. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Sobel BE; Hardison RM; Genuth S; Brooks MM; McBane RD; Schneider DJ; Pratley RE; Huber K; Wolk R; Krishnaswami A; Frye RL; Circulation; 2011 Aug; 124(6):695-703. PubMed ID: 21768545 [TBL] [Abstract][Full Text] [Related]
30. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853 [TBL] [Abstract][Full Text] [Related]
31. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616 [TBL] [Abstract][Full Text] [Related]
32. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Betteridge DJ; Vergès B Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239 [TBL] [Abstract][Full Text] [Related]
33. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076 [TBL] [Abstract][Full Text] [Related]
34. Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus. Forst T; Weber MM; Löbig M; Lehmann U; Müller J; Hohberg C; Friedrich C; Fuchs W; Pfützner A Clin Sci (Lond); 2010 Jul; 119(8):345-51. PubMed ID: 20509857 [TBL] [Abstract][Full Text] [Related]
35. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice. Hershon KS; Hershon PM Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922 [TBL] [Abstract][Full Text] [Related]
36. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497 [TBL] [Abstract][Full Text] [Related]
37. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Tan MH; Glazer NB; Johns D; Widel M; Gilmore KJ Curr Med Res Opin; 2004 May; 20(5):723-8. PubMed ID: 15140339 [TBL] [Abstract][Full Text] [Related]
38. Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus. Jeong IK; Chung CH; Zhou Z; Han JH; Duan R; Edralin DM; Rodriguez A J Diabetes; 2017 Apr; 9(4):396-404. PubMed ID: 27171584 [TBL] [Abstract][Full Text] [Related]
39. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea. Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133 [TBL] [Abstract][Full Text] [Related]
40. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Jialal I; Abby SL; Misir S; Nagendran S Metab Syndr Relat Disord; 2009 Jun; 7(3):255-8. PubMed ID: 19344229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]